RE: Β£9 million grant3 Oct 2024 08:37
PI,
FYI - Saliva Test for Prostate Cancer is in the Transform Trial
The saliva test also identified a higher proportion of aggressive cancers, which are fast growing and likely to spread: 55 percent of cases it identified were aggressive, compared to 35 percent for the PSA test. The spit test was also more accurate than an MRI scan for those with high genetic risk: 119 men in the study had prostate cancer confirmed by a biopsy that was not detected by the MRI.
Some 62 of the 187 cancers diagnosed required treatment and the rest were put on active monitoring. The saliva test, which costs less than Β£200, will now be evaluated in a Β£42 million trial of the most promising technology.
The TRANSFORM trial, hailed as the largest prostate cancer screening study in two decades, is poised to pave the way for a national screening programme. Researchers are also exploring other methods such as the PSA test and expedited 12-minute MRI scans.